In September 2015, the Academy of Medical Sciences, in partnership with the Association of the British Pharmaceutical Industry, held a joint workshop on ‘Real world evidence’.
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK. The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
The workshop brought together participants from across industry, regulatory, academia and policy to explore the acceptability of real world evidence in regulatory and Health Technology Assessment decision-making, aspirations for the use of this evidence in a regulatory context, challenges to the acceptability and steps to overcome these.
The report summarises the presentations and discussions from the meeting, which highlighted the potential of real world evidence to significantly impact how medicines are evaluated.